Medicine and Health

Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancer

H. Hockings, E. Lakatos, et al.

Discover how Adaptive Therapy (AT) is revolutionizing the treatment of chemotherapy-resistant ovarian cancer, potentially leading to better patient outcomes. Conducted by renowned researchers including Helen Hockings and Eszter Lakatos, this study reveals how exploiting the fitness costs of drug-resistant cells can extend survival in ovarian cancer patients. Intriguing findings from patient samples further support the potential of AT, paving the way for a multicenter phase 2 trial.